Imikhiqizo

Izindlela zokwelapha i-T2DM, isifo esibonakala ngokukhubazeka okukabili kokungasebenzi kahle kwe-islet cell kanye nokumelana ne-insulin, kufaka phakathi ama-ejenti akhulisa ukukhiqizwa kwe-insulin ngamanyikwe (ama-secretagogues), ama-ejenti akhulisa ukuzwela kwezitho ezihlosiwe ku-insulin (izinzwa), kanye I-Liraglutide, i-GLP-1 receptor agonist ukuze ifinyelele emakethe, ine-homology engama-97% ku-GLP-1 enezinguquko ezimbili kuphela ze-amino acid kanye nokwengezwa kweketango elihlangothini le-acid enamafutha.Ngokukhethekile, i-lysine esendaweni 34 ithathelwe indawo i-arginine, futhi i-lysine esendaweni 26 ishintshiwe ngeketango le-C16 acyl nge-spacer ye-glutamoyl.I-Liraglutide ithola ukumelana nokuwohloka kwe-DPP-4 kusuka ekuthambekeni kwayo ukwenza ama-micelles futhi ibophe ku-albumin.Ngokungafani ne-exenatide eyandulele yona, edinga imijovo emibili yansuku zonke engaphansi kwesikhumba ngaphambi kokudla kokuqala nokokugcina kosuku, i-liraglutide ivunyelwe njengomuthi wokwelapha kanye ngosuku futhi ingasetshenziswa ngokuhlangana ne-metformin noma i-sulfonylurea ezigulini ezinokulawulwa okunganele kwe-glycemic ngokunye. i-monotherapy noma ukwelashwa okuhlangene okubili.Kuvunyelwe futhi ngokuhlanganiswa nokwelashwa okumbaxambili kwe-metformin kanye ne-thiazolidinedione ezigulini ezinokulawulwa okwanele kwe-glycemic.I-Liraglutide ibonise amandla abophayo angu-61 pM (EC50= 55 pM ye-GLP-1) kumamukeli we-GLP-1 womuntu.